Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sensitivity of the NIH Toolbox Cognition Battery to Stimulant Treatment in Intellectual Disabilities
NCT05301361Phase 1Enrolling by invitation
- Sponsor
- University of California, Davis
- Start
- Feb 2023
- Primary completion
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of methylphenidate hydrochloride extended-release chewable tablet in attention deficit hyperactivity disorder (ADHD) (2 arms), sponsored by University of California, Davis. Primary endpoint: Composite score of NIH Toolbox Cognition Battery Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests at 11 weeks. Started Feb 2023; status: enrolling by invitation.
02
Drugs
methylphenidate hydrochloride extended-release chewable tablet
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT05301361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05301361.